Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) EPS (Weighted Average and Diluted) (2018 - 2026)

Catalyst Pharmaceuticals filings provide 9 years of EPS (Weighted Average and Diluted) readings, the most recent being $0.5 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 11.11% to $0.5 in Q1 2026 year-over-year; TTM through Mar 2026 was $1.74, a 10.83% increase, with the full-year FY2025 number at $1.68, up 28.24% from a year prior.
  • EPS (Weighted Average and Diluted) hit $0.5 in Q1 2026 for Catalyst Pharmaceuticals, up from $0.41 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.5 in Q1 2026 to a low of -$0.29 in Q3 2023.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was $0.33 (2023), compared with a mean of $0.29.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 245.0% in 2023 and later soared 220.69% in 2024.
  • Catalyst Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $0.23 in 2022, then surged by 34.78% to $0.31 in 2023, then skyrocketed by 41.94% to $0.44 in 2024, then dropped by 6.82% to $0.41 in 2025, then increased by 21.95% to $0.5 in 2026.
  • The last three reported values for EPS (Weighted Average and Diluted) were $0.5 (Q1 2026), $0.41 (Q4 2025), and $0.42 (Q3 2025) per Business Quant data.